Anita Mitra was appointed as a consultant in clinical oncology at University College London Hospitals in 2010. She qualified in medicine from Imperial College London School of Medicine. She trained in oncology at the Royal Marsden and at University College London Hospitals and completed an MD in the genetics of prostate cancer at the Institute of Cancer Research.
She has a busy prostate, bladder and penile cancer practice. She works within two multidisciplinary teams. She has an interest in technical radiotherapy and is the lead for stereotactic radiotherapy for urological malignancies for the sector. She is part of the UCLH team delivering HDR brachytherapy for the surrounding hospitals. She has a sub-speciality interest in penile cancer management. She is a principal investigator for a variety of national and international studies in prostate, bladder and penile cancer.
- Prostate cancer
- Bladder cancer
- Stereotactic radiotherapy
- HDR brachytherapy
Most recent publications
Long term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: A systematic review and meta-analysis, Singh S, Moore C, Punwani S, Mitra AV, Bandula S, Accepted for publication in Prostate Cancer and Prostatic Diseases 2020
The management of sexual dysfunction resulting from radiotherapy and androgen deprivation therapy to treat prostate cancer: A comparison of uro‐oncology practice according to disease stage, Kinnaird W, Kirby MG, Mitra A, Davda R, Jenkins V, Payne H, International Journal of Clinical Practice First published: 01 December 2020
Clinical outcomes of a randomised trial of adaptive plan of the day treatment in patients receiving ultra-hypofractionated weekly radiotherapy for bladder cancer. Huddart R, Hafeez S, Lewis R, McNair H, Syndikus I, Henry A, Staffurth J, Dewan M, Vassallo-Bonner C, Moinuddin SA, Birtle A, Horan G, Rimmer Y, Venkitaraman R, Khoo V, Mitra A, Hughes S, Gibbs S, Kapur G, Baker A, Hansen VN, Patel E, Hall E; HYBRID Investigators. Int J Radiat Oncol Biol Phys. 2020 Dec 11: S0360-3016(20)34640-X
Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy. Kanthabalan A, Arya M, Freeman A, Mitra AV, Payne H, Peters M, Shah TT, Emberton M, Ahmed HU. J Urol. 2020 Nov;204(5):950-955.Epub 2020 Jun 30
The management of sexual dysfunction resulting from radiotherapy and androgen deprivation therapy: A survey of current UK practice, Kinniard W, Davda R, Mitra A, Payne H, July 2020 European Urology Open Science 19:e1131
Early Prostate-specific Antigen Response in Men Undergoing Oncological Management for High-Ris Non-metastatic Prostate Cancer , M Stancliffe, D Pendse, H Payne, A Mitra, U McGovern, R Davda, Clin Oncol (R Coll Radiol) 2020 Jul;32(7):478-479 Epub 2020 Apr 3.
Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance, Hafeez S, Webster A,Hansen V,McNair H,Warren-Oseni K,Patel E,Choudhury A,Creswell J, Foroudi F,Henry A, Kron T,McLaren DB, Mitra A, Mostafid H, Saunders D, Miles E, Griffin C,Lewis R, Hall E, Huddart R, BMJ Open 2020;0:e041005. doi:10.1136/bmjopen-2020-041005
Management of penile cancer patients during the COVID-19 pandemic: an eUROGEN accelerated Delphi consensus study by Mr. Asif Muneer, June 2020 European Urology
The use of body composition parameters as predictors of metastatic disease and prognostic indicators in penile cancer – a eUROGEN centre study Christodoulidou M, Lal S, Ramachandran N, Burden S, Gibson D, Alnajjar H, Mitra A, Richards T, Muneer A Eur Urol Open Sci July 2020;19(Suppl 2):e303
Multidisciplinary Approach for the Management of Penoscrotal Extramammary Paget’s disease – an eUROGEN study, Christodoulidou; Alnajjar HM; Parnham A; Khetrapal P; Freeman A; Haider A; Mitra A; Bunker CB, Muneer A, Journal: Urologic Oncology: Seminars and Original Investigations, Manuscript Number: URO-D-18-00253R